Prior to joining Taiwania, Ita has combined 20 years of both life sciences buy-side (public equities, venture capital, private equity), sell-side (equity research, investment banking) and biotech operational experiences across the US and in Asia. Ita's investment expertise across both direct investment as well as the secondary market in investing and managing expansion to late-stage biotech and medtech companies.
Some of his notable deals include Advancis Pharmaceuticals (IPO), PTC Therapeutics (IPO), Anadys Pharmaceuticals (Acquired by Roche), Arpida AG (IPO), CombinatoRx (IPO), Morphotek (Acquired by Eisai), U-Systems (Acquired by GE Healthcare), MBI Biotech (IPO) , PharmaEssentia (IPO) and Eirgenex (IPO).
Taiwania Capital Management Corporation
Taiwania Capital is a venture capital firm founded in August 2017 by the National Development Fund of the Executive Yuan along with private enterprises. As of now, Taiwania Capital manages 8 funds and focuses on investing in early to growth-stage technology and biotech startups in Taiwan, the U.S., Japan, Southeast Asia and Central East Europe. Its mission is to connect Taiwan's robust tech and biotech ecosystems with global innovations, providing resources to its portfolio companies to enhance their growth and market penetration.